Janis leads cross-functional activities in regulatory science and international health policy for IFPMA, while partnering with policy experts and stakeholders to strengthen the pharmaceutical regulatory environment.
She is responsible for guiding the organization’s regulatory team to successfully deliver its policy objectives and advocate for improved regulatory system strengthening.
Prior to joining IFPMA,Janis worked in quality assurance and regulatory compliance fora US-based multinational company that specializes in supplying custom value-added food products to a world leading food service and retail food brand.
Janis holds a Master of Science in Communication-Public Relations and a Bachelor of Science in Agriculture-Food Science.
Strong, capable, and efficient regulatory systems are fundamental to improving access to medicines and vaccines. All of us have a responsibility to engage in these conversations, collaborate, and improve the lives and livelihoods of patients globally.
More from Janis
Advancing regulatory reliance on a global scale
Next week, Japan will host expert discussions on strengthening regulatory systems, fostering international collaboration, and advancing towards universal health coverage. This discussion is part of the Asia Partnership Conference of Pharmaceutical Associations (APAC), an industry-driven initiative focused on expediting the availability of innovative medicines across Asia. For more than 10 years, APAC has served as...
Read more
Applying lessons learned on regulatory agility: Perspectives from national regulatory authorities
Regulatory agility played a crucial role in speeding up the development and approval of medicines and vaccines during the COVID-19 pandemic. The insights gained from this success are valuable for continually strengthening regulatory frameworks, both in emergency and non-emergency situations. IFPMA collaborated with external researchers to gather insights from national regulatory authorities and pharmaceutical companies on the success factors behind regulatory agility, especially ahead of future pandemics.
Read more
What role did regulatory agilities play during the COVID-19 pandemic and what can we learn from this experience?
The COVID-19 pandemic has had a drastic impact on all the activities related to the development, assessment and approval of medicines and vaccines, unlocking opportunities to work in more agile and collaborative manners. Janis Bernat explains what we can learn from this experience.
Read more